The Securities and Exchange Commission has not necessarily reviewed
the information in this filing and has not determined if it is
accurate and complete.
The reader should not assume that the information is accurate
and complete.
|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D
Notice of Exempt Offering of Securities
| | OMB APPROVAL | | OMB Number: | 3235-0076 | | Expires: | August 31, 2015 | | Estimated average burden | | hours per response: | 4.00 |
|
|
1. Issuer's Identity
| CIK (Filer ID Number) | Previous Names | | Entity Type |
|---|
| 0001631487 | | CollPlant Holdings Ltd. | | CollPlant Biotechnologies Ltd. |
| | X | Corporation | | Limited Partnership | | Limited Liability Company | | General Partnership | | Business Trust | | Other (Specify) |
|
| Name of Issuer |
|---|
| CollPlant Biotechnologies Ltd |
| Jurisdiction of Incorporation/Organization |
|---|
| ISRAEL |
| Year of Incorporation/Organization |
|---|
| X | Over Five Years Ago | | Within Last Five Years (Specify Year) | | | Yet to Be Formed |
|
2. Principal Place of Business and Contact Information
| Name of Issuer |
|---|
| CollPlant Biotechnologies Ltd |
| Street Address 1 | Street Address 2 |
|---|
| 4 OPPENHEIMER, WEIZMANN SCIENCE PARK | |
| City | State/Province/Country | ZIP/PostalCode | Phone Number of Issuer |
|---|
| REHOVOT | ISRAEL | 7670104 | +972 73 232 5600 |
3. Related Persons
| Last Name | First Name | Middle Name |
|---|
| Tal | Yehiel | |
| Street Address 1 | Street Address 2 |
|---|
| COLLPLANT BIOTECHNOLOGIES LTD | 4 Oppenheimer, Weizmann Science Park |
| City | State/Province/Country | ZIP/PostalCode |
|---|
| Rehovot | ISRAEL | 7670104 |
| Relationship: | X | Executive Officer | X | Director | | Promoter |
|---|
Clarification of Response (if Necessary):
Chief Executive Officer and Interim Chairman of the Board of Directors
| Last Name | First Name | Middle Name |
|---|
| Rotem | Eran | |
| Street Address 1 | Street Address 2 |
|---|
| COLLPLANT BIOTECHNOLOGIES LTD | 4 Oppenheimer, Weizmann Science Park |
| City | State/Province/Country | ZIP/PostalCode |
|---|
| Rehovot | ISRAEL | 7670104 |
| Relationship: | X | Executive Officer | | Director | | Promoter |
|---|
Clarification of Response (if Necessary):
Deputy Chief Executive Officer and Chief Financial Officer
| Last Name | First Name | Middle Name |
|---|
| Fahimipoor | Oren | |
| Street Address 1 | Street Address 2 |
|---|
| COLLPLANT BIOTECHNOLOGIES LTD | 4 Oppenheimer, Weizmann Science Park |
| City | State/Province/Country | ZIP/PostalCode |
|---|
| Rehovot | ISRAEL | 7670104 |
| Relationship: | X | Executive Officer | | Director | | Promoter |
|---|
Clarification of Response (if Necessary):
Vice President, Operations
| Last Name | First Name | Middle Name |
|---|
| Bensimon | Philippe | |
| Street Address 1 | Street Address 2 |
|---|
| COLLPLANT BIOTECHNOLOGIES LTD | 4 Oppenheimer, Weizmann Science Park |
| City | State/Province/Country | ZIP/PostalCode |
|---|
| Rehovot | ISRAEL | 7670104 |
| Relationship: | X | Executive Officer | | Director | | Promoter |
|---|
Clarification of Response (if Necessary):
Vice President, Regulatory Affairs and Quality Assurance
| Last Name | First Name | Middle Name |
|---|
| Seror | Jasmine | |
| Street Address 1 | Street Address 2 |
|---|
| COLLPLANT BIOTECHNOLOGIES LTD | 4 Oppenheimer, Weizmann Science Park |
| City | State/Province/Country | ZIP/PostalCode |
|---|
| Rehovot | ISRAEL | 7670104 |
| Relationship: | X | Executive Officer | | Director | | Promoter |
|---|
Clarification of Response (if Necessary):
Vice President, Product Development
| Last Name | First Name | Middle Name |
|---|
| Bagley | Bowman | |
| Street Address 1 | Street Address 2 |
|---|
| COLLPLANT BIOTECHNOLOGIES LTD | 4 Oppenheimer, Weizmann Science Park |
| City | State/Province/Country | ZIP/PostalCode |
|---|
| Rehovot | ISRAEL | 7670104 |
| Relationship: | X | Executive Officer | | Director | | Promoter |
|---|
Clarification of Response (if Necessary):
Vice President, Commercial North America
| Last Name | First Name | Middle Name |
|---|
| Abelis | Bar | |
| Street Address 1 | Street Address 2 |
|---|
| COLLPLANT BIOTECHNOLOGIES LTD | 4 Oppenheimer, Weizmann Science Park |
| City | State/Province/Country | ZIP/PostalCode |
|---|
| Rehovot | ISRAEL | 7670104 |
| Relationship: | X | Executive Officer | | Director | | Promoter |
|---|
Clarification of Response (if Necessary):
Vice President, Legal
| Last Name | First Name | Middle Name |
|---|
| Havron | Abraham | |
| Street Address 1 | Street Address 2 |
|---|
| COLLPLANT BIOTECHNOLOGIES LTD | 4 Oppenheimer, Weizmann Science Park |
| City | State/Province/Country | ZIP/PostalCode |
|---|
| Rehovot | ISRAEL | 7670104 |
| Relationship: | | Executive Officer | X | Director | | Promoter |
|---|
Clarification of Response (if Necessary):
| Last Name | First Name | Middle Name |
|---|
| Penn | Elan | |
| Street Address 1 | Street Address 2 |
|---|
| COLLPLANT BIOTECHNOLOGIES LTD | 4 Oppenheimer, Weizmann Science Park |
| City | State/Province/Country | ZIP/PostalCode |
|---|
| Rehovot | ISRAEL | 7670104 |
| Relationship: | | Executive Officer | X | Director | | Promoter |
|---|
Clarification of Response (if Necessary):
| Last Name | First Name | Middle Name |
|---|
| Zarzewsky | Joseph | |
| Street Address 1 | Street Address 2 |
|---|
| COLLPLANT BIOTECHNOLOGIES LTD | 4 Oppenheimer, Weizmann Science Park |
| City | State/Province/Country | ZIP/PostalCode |
|---|
| Rehovot | ISRAEL | 7670104 |
| Relationship: | | Executive Officer | X | Director | | Promoter |
|---|
Clarification of Response (if Necessary):
| Last Name | First Name | Middle Name |
|---|
| Evans | Hugh | |
| Street Address 1 | Street Address 2 |
|---|
| COLLPLANT BIOTECHNOLOGIES LTD | 4 Oppenheimer, Weizmann Science Park |
| City | State/Province/Country | ZIP/PostalCode |
|---|
| Rehovot | ISRAEL | 7670104 |
| Relationship: | | Executive Officer | X | Director | | Promoter |
|---|
Clarification of Response (if Necessary):
| Last Name | First Name | Middle Name |
|---|
| Lask | Alisa | |
| Street Address 1 | Street Address 2 |
|---|
| COLLPLANT BIOTECHNOLOGIES LTD | 4 Oppenheimer, Weizmann Science Park |
| City | State/Province/Country | ZIP/PostalCode |
|---|
| Rehovot | ISRAEL | 7670104 |
| Relationship: | | Executive Officer | X | Director | | Promoter |
|---|
Clarification of Response (if Necessary):
4. Industry Group
| | Agriculture | | Banking & Financial Services | | | | Commercial Banking | | | Insurance | | | Investing | | | Investment Banking | | | Pooled Investment Fund | | | | Hedge Fund | | | Private Equity Fund | | | Venture Capital Fund | | | Other Investment Fund |
| |
Is the issuer registered as
an investment company under
the Investment Company
Act of 1940?
| | | | | Other Banking & Financial Services |
| | | Business Services | | Energy | | | | | | | | | | | | |
| | Health Care | | | | | | | | | | | | | Manufacturing | | Real Estate | | | | | | | | | | |
| | Retailing | | Restaurants | | Technology | | | | | | | | Travel | | | | | | | | Tourism & Travel Services |
| | | | Other |
|
5. Issuer Size
| Revenue Range | OR | Aggregate Net Asset Value Range |
|---|
|
| No Revenues |
| No Aggregate Net Asset Value |
|
| $1 - $1,000,000 |
| $1 - $5,000,000 |
|
| $1,000,001 - $5,000,000 |
| $5,000,001 - $25,000,000 |
|
| $5,000,001 - $25,000,000 |
| $25,000,001 - $50,000,000 |
|
| $25,000,001 - $100,000,000 |
| $50,000,001 - $100,000,000 |
|
| Over $100,000,000 |
| Over $100,000,000 |
| X | Decline to Disclose |
| Decline to Disclose |
|
| Not Applicable |
| Not Applicable |
6. Federal Exemption(s) and Exclusion(s) Claimed (select
all that apply)
| | Rule 504(b)(1) (not (i), (ii) or (iii)) | |
| Investment Company Act Section 3(c) | |
| Section 3(c)(1) |
| Section 3(c)(9) |
| |
| Section 3(c)(2) |
| Section 3(c)(10) |
| |
| Section 3(c)(3) |
| Section 3(c)(11) |
| |
| Section 3(c)(4) |
| Section 3(c)(12) |
| |
| Section 3(c)(5) |
| Section 3(c)(13) |
| |
| Section 3(c)(6) |
| Section 3(c)(14) |
| |
|
|
|
| Rule 504 (b)(1)(i) |
|
| Rule 504 (b)(1)(ii) |
|
| Rule 504 (b)(1)(iii) |
|
| Rule 505 |
| X | Rule 506(b) |
|
| Rule 506(c) |
|
| Securities Act Section 4(a)(5) |
|
| |
7. Type of Filing
| X | New Notice | | Date of First Sale | 2026-02-04 | |
| First Sale Yet to Occur |
|
| Amendment |
8. Duration of Offering
| Does the Issuer intend this offering to last more than
one year? | | |
9. Type(s) of Securities Offered (select all that apply)
| X | Equity |
| Pooled Investment Fund Interests |
|
| Debt |
| Tenant-in-Common Securities |
| X | Option, Warrant or Other Right to Acquire Another
Security |
| Mineral Property Securities |
| X | Security to be Acquired Upon Exercise of Option,
Warrant or Other Right to Acquire Security | X | Other (describe) |
| |
10. Business Combination Transaction
| Is this offering being made in connection with a
business combination transaction, such as a merger, acquisition or
exchange offer? | | |
Clarification of Response (if Necessary):
11. Minimum Investment
| Minimum investment accepted from any outside investor | $0 | USD |
12. Sales Compensation
| Recipient | | Recipient CRD Number |
| None |
|
| H.C. Wainwright & Co. LLC | 000000375 |
| (Associated) Broker or Dealer | X | None |
| | (Associated) Broker or Dealer CRD Number | X | None |
|
| None | None |
| Street Address 1 | Street Address 2 |
|---|
| 430 Park Avenue | 3rd Floor |
| City | State/Province/Country | ZIP/Postal Code |
| New York | NEW YORK | 10022 |
State(s) of Solicitation (select all that apply)
Check “All States” or check individual States
|
| All States |
| |
|
13. Offering and Sales Amounts
| Total Offering Amount | $4,000,000 | USD | |
| Total Amount Sold | $4,000,000 | USD |
| Total Remaining to be Sold | $0 | USD | |
Clarification of Response (if Necessary):
Offering of unregistered series A warrants to purchase 1,600,000 ordinary shares, and unregistered series B warrants to purchase 1,600,000 ordinary shares. The total offering amount does not reflect warrants issued to placement agent (see Item 15).14. Investors
| Select if securities in the offering have been or may
be sold to persons who do not qualify as accredited investors, and
enter the number of such non-accredited investors who already have
invested in the offering. | |
| Regardless of whether securities in the offering have
been or may be sold to persons who do not qualify as accredited
investors, enter the total number of investors who already have
invested in the offering: | |
15. Sales Commissions & Finder's Fees Expenses
Provide separately the amounts of sales commissions and
finders fees expenses, if any. If the amount of an expenditure is not
known, provide an estimate and check the box next to the amount.
| Sales Commissions | $210,950 | USD | |
| Finders' Fees | $0 | USD | |
Clarification of Response (if Necessary):
H.C. Wainwright is entitled to 7.0% of gross proceeds cash fee, 1.0% of gross proceeds management fee, $35,000 non-accountable expenses, $15,950 clearing fees and warrants to purchase 96,000 ordinary shares at $1.5625/share for 5 years. This is estimated.16. Use of Proceeds
Provide the amount of the gross proceeds of the offering
that has been or is proposed to be used for payments to any of the
persons required to be named as executive officers, directors or
promoters in response to Item 3 above. If the amount is unknown,
provide an estimate and check the box next to the amount.
Clarification of Response (if Necessary):
The Company intends to use the net proceeds for general corporate purposes, which may include but are not limited to, working capital and funding research and development programs.Signature and Submission
Please verify the information you have entered and review
the Terms of Submission below before signing and clicking SUBMIT below
to file this notice.
Terms of Submission
| In submitting this notice, each issuer named above is: |
- Notifying the SEC and/or each State in which this notice is
filed of the offering of
securities described and undertaking to furnish them, upon written request,
in the accordance with applicable
law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and,
the Securities Administrator
or other legally designated officer of the State in which the
issuer maintains its principal
place of business and any State in which this notice is filed, as its
agents for service of
process, and agreeing that these persons may accept service on its
behalf, of any notice,
process or pleading, and further agreeing that such service may be made
by registered or
certified mail, in any Federal or state action, administrative proceeding,
or arbitration
brought against it in any place subject to the jurisdiction of the
United States, if the
action, proceeding or arbitration (a) arises out of any activity in
connection with the
offering of securities that is the subject of this notice, and (b) is
founded, directly or
indirectly, upon the provisions of: (i) the Securities Act of 1933, the
Securities Exchange
Act of 1934, the Trust Indenture Act of 1939, the Investment Company
Act of 1940, or the
Investment Advisers Act of 1940, or any rule or regulation under any of
these statutes, or (ii)
the laws of the State in which the issuer maintains its principal
place of business or any State
in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505
exemption, the issuer is not disqualified
from relying on Rule 505 for one of the reasons stated in Rule
505(b)(2)(iii) or Rule 506(d).
|
Each Issuer identified above has read this notice, knows the
contents to be true, and has duly caused this notice to be signed on
its behalf by the undersigned duly authorized person.
For signature, type in the signer's name or other letters or
characters adopted or authorized as the signer's signature.
| Issuer | Signature | Name of Signer | Title | Date |
|---|
| CollPlant Biotechnologies Ltd | /s/ Eran Rotem | Eran Rotem | Deputy Chief Executive Officer and Chief Financial Officer | 2026-02-17 |
Persons who respond to the collection of information
contained in this form are not required to respond unless the form
displays a currently valid OMB number.
* This undertaking does not affect any limits Section 102(a)
of the National Securities Markets
Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11,
1996)] imposes on the ability of States to
require information. As a result, if the securities that are the subject of
this Form D are "covered securities" for purposes
of NSMIA, whether in all instances or due to the nature of the offering
that is the subject of this Form D, States cannot
routinely require offering materials under this undertaking or otherwise and
can require offering materials only to the
extent NSMIA permits them to do so under NSMIA's preservation of their
anti-fraud authority.
Tweet
Share
E-mail